Biotech | May 02, 2022
NORD announces over US $ 100,000 in grant funding available for rare disease research
Three RFPs now open for qualified researchers through NORD's Jayne Holtzer rare disease research grants program
Three RFPs now open for qualified researchers through NORD's Jayne Holtzer rare disease research grants program
Avacc 3 has significant advantages over existing whooping cough vaccines
Blood test for early detection of Alzheimer's Disease (AD) risk will lead to better patient care, physicians say; US. adults call for earlier evaluation and more education
The companies expect to complete the submission of the NDA for treatment of MDD in the second half of 2022; associated filing for postpartum depression is anticipated in the first half of 2023
The planned Phase 1 study is a double-blind, randomized, placebo-controlled dose-escalation study in healthy adult subjects and AD patients
A Promising Innovative Medicine (PIM) designation is an early indication that leniolisib is a candidate for the MHRA's Early Access to Medicines Scheme
Covaxin was earlier approved for children 12-18 years of age
A separate global Phase 3 study of S-217622 is underway aiming to recruit participants globally to support regulatory filings this year
Under the agreement, Porton Advanced will provide services to accelerate the development, production and registration of breakthrough cell therapies currently being developed by Sinorda Biomedicine
Bringing together Bristol Myers Squibb and Celgene on one clinical trial management system, company goes live with Vault CTMS in record speed
Subscribe To Our Newsletter & Stay Updated
